Vista Pharma submits ANDA to USFDA for cardiac drug

Vista Pharmaceuticals informed that the company has submitted an Abbreviated New Drug Application (ANDA) to USFDA on September 25, 2017 for a cardiac drug.

Sep 26, 2017 08:09 IST India Infoline News Service

Vista Pharmaceuticals informed that the company has submitted an Abbreviated New Drug Application (ANDA) to USFDA on September 25, 2017 for a cardiac drug.
 
This project is partnered with a US-based company, said Vista Pharmaceuticals in a BSE filing on Tuesday.
 
The stock of Vista Pharmaceuticals was buzzing on the bourses as it soared nearly 5% intraday. It was trading at Rs 52.55 per share, up by Rs 1.40 or 2.79% as at 1418 hours on Tuesday, on the BSE. The stock hit an intraday high and low of Rs 52.60 and Rs 49.15, respectively.
 
Vista Pharmaceuticals traded on a new 52-week high value of Rs 52.60 during Tuesday’s trade on the BSE. The stock had hit its 52-week low of Rs 15.50 on November 22, 2016, on the BSE.
 
Vista Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations. 

Related Story